| Q36742881 | A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery |
| Q37118460 | Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology. |
| Q37074780 | Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery |
| Q36858404 | Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters |
| Q41897007 | Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. |
| Q33187648 | Pharmacological effects of formulation vehicles : implications for cancer chemotherapy |
| Q47148643 | Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice |
| Q36449367 | Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer |
| Q59796111 | Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans |
| Q38799790 | Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity |
| Q35765100 | Tumor-targeting drug delivery of new-generation taxoids |
| Q36470377 | Update on taxane development: new analogs and new formulations |